FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option

In this articleGILDThe logo of Gilead Sciences pharmaceutical company is seen in Oceanside, California, April 29, 2020.Mike Blake | ReutersThe Food and Drug Administration on Wednesday approved Gilead's twice-yearly antiviral injection for preventing HIV – a milestone that the company and some experts say could help bring the world closer to ending the decades-long epidemic caused by the virus. But the launch of the injectable drug, lenacapavir, faces a set of potential threats, including the Trump administ ...